Proviron Half-Life: Why the Metabolite Matters More Than the Parent Drug and What That Means for Your Dosing Schedule
When you search for the Proviron half-life, every source gives you the same number: 12 to 13 hours. That figure comes directly from the Bayer prescribing information and reflects the terminal elimination rate of the parent compound mesterolone. It is accurate, but it is incomplete. Mesterolone does not simply disappear after 12 hours. It converts into a biologically active metabolite called 1-alpha-methyl-androsterone that continues to exert androgenic effects well beyond the clearance window of the parent drug. Understanding this two-phase pharmacokinetic profile is what separates effective Proviron dosing from guesswork. Hemi Pharma UK supplies mesterolone in a 25mg tablet format specifically because precise dose timing depends on knowing exactly how this compound behaves in your body.
What Is the Actual Proviron Half-Life According to the Manufacturer?
The official Bayer summary of product characteristics (SmPC), updated November 2023, states that serum levels of mesterolone decrease with a terminal half-life of 12 to 13 hours. Peak plasma concentration (Cmax) reaches approximately 3.8 ng/mL within about 2 hours of oral administration. The absolute bioavailability of mesterolone is approximately 3% of the oral dose. Mesterolone binds to serum proteins at 98%: roughly 40% to albumin and 58% to sex hormone-binding globulin (Bayer Proviron SmPC, 2023).
In metabolite form, mesterolone is excreted approximately 80% through the urine and 13% through the faeces. Within seven days, 93% of the administered dose has been eliminated, with half of the urinary excretion occurring within the first 24 hours. These figures describe the total clearance of all mesterolone-derived compounds, not just the parent drug itself.
Why Does Only 3% of Your Proviron Tablet Reach Systemic Circulation?
This question matters because it explains the paradox at the centre of mesterolone pharmacology. You swallow a 25mg tablet. Your liver metabolises 97% of it during first-pass processing. Only about 0.75mg of intact mesterolone enters your bloodstream. By conventional pharmacological standards, this looks like an almost useless drug. Yet mesterolone has been prescribed clinically for over 60 years with documented efficacy in hypogonadism, infertility, and libido restoration.
The resolution is that the first-pass metabolism is not destruction. It is transformation. The liver converts the majority of ingested mesterolone into metabolites, the most significant being 1-alpha-methyl-androsterone (1-alpha-methyl-5-alpha-androstan-3-alpha-ol-17-one). This is the compound identified by Schänzer and Donike (1992) as the major urinary metabolite when they characterised mesterolone metabolism using gas chromatography and mass spectrometry at the German Sport University Cologne. They confirmed that 1-alpha-methyl-androsterone was the dominant metabolic product, formed through reduction of the 3-keto group and oxidation of the 17-beta-hydroxyl group (Journal of Steroid Biochemistry and Molecular Biology, 42(5), 533-541).
A secondary metabolite, 1-alpha-methyl-5-alpha-androstane-3-alpha,17-beta-diol, was also detected. Both metabolites were conjugated to glucuronic acid for urinary excretion. The parent compound itself and the intermediate 3-alpha,17-beta-dihydroxysteroid were also present in urine, confirming that multiple mesterolone-derived androgens circulate simultaneously after a single dose.
Is 1-Alpha-Methyl-Androsterone Biologically Active or Just a Waste Product?
This is the critical question that most Proviron half-life discussions ignore entirely. Androsterone itself, the unmethylated version of this metabolite, is a known weak androgen and neurosteroid. It acts as a positive allosteric modulator of the GABA-A receptor, contributing to anxiolytic and mood-stabilising effects. It also retains weak androgen receptor binding activity.
The 1-alpha-methyl modification alters the molecule’s metabolic stability. Methylation at the 1-alpha position is the same structural feature that makes mesterolone itself resistant to 3-alpha-HSD inactivation in some tissue contexts. While 1-alpha-methyl-androsterone is less potent than the parent drug at the androgen receptor, it is not inert. It persists in circulation and in tissue longer than mesterolone itself, creating a pharmacokinetic tail that extends the compound’s total duration of androgenic activity beyond what the 12-to-13-hour parent half-life would suggest.
The practical implication is that a single 25mg dose of Proviron produces a biphasic activity curve. The first phase, driven by intact mesterolone, peaks at roughly 2 hours and substantially declines by 8 to 10 hours. The second phase, driven by 1-alpha-methyl-androsterone and the intermediate diol metabolite, extends the total androgenic exposure further, though at reduced intensity.
How Does the Proviron Half-Life Compare to Other Oral Androgens?
Context makes the 12-to-13-hour figure more meaningful. Methyltestosterone, the oldest oral androgen still in clinical use, has an elimination half-life of approximately 2.5 to 3 hours. Methandrostenolone (Dianabol) clears in 3 to 6 hours. Oxandrolone (Anavar) has a half-life of about 9 hours. Oxymetholone (Anadrol) sits at roughly 8 to 9 hours. Stanozolol (Winstrol) in its oral form has a half-life of approximately 9 hours.
Mesterolone, at 12 to 13 hours, has the longest parent-compound half-life of any commonly used oral androgen. This is a direct consequence of its 1-alpha-methylation. Unlike the 17-alpha-alkylation used by most oral steroids to survive hepatic metabolism, 1-alpha-methylation provides a different form of metabolic resistance. It does not protect the 17-beta-hydroxyl group from oxidation the way 17-alpha-alkylation does (which is why mesterolone is not hepatotoxic), but it does slow the rate of complete structural degradation, giving the parent compound and its primary metabolite a longer functional window.
What Does the Proviron Half-Life Mean for Dosing: Once Daily or Twice Daily?
The Bayer prescribing information recommends dosing between one and three tablets daily (25 to 75mg), and clinical practice typically uses twice-daily dosing at 25mg per administration when the total daily dose is 50mg. The pharmacokinetic data supports this approach.
With a 12-to-13-hour half-life, a single morning dose of 25mg will produce meaningful serum mesterolone levels through roughly 8 to 10 hours of the day, with residual metabolite activity extending into the evening. A second 25mg dose in the evening ensures that the SHBG displacement effect and DHT-type receptor activation are maintained around the clock. The metabolite tail from each dose overlaps with the active phase of the next dose, creating a relatively stable total androgenic exposure across 24 hours.
For men using Proviron on testosterone replacement therapy, where the goal is consistent SHBG suppression and free testosterone optimisation, twice-daily dosing at 25mg is the standard clinical approach. Once-daily dosing at 25mg is acceptable for men who find the SHBG-lowering effect sufficient at that dose, particularly if their SHBG is only moderately elevated (30 to 40 nmol/L rather than above 50).
For men using Proviron as part of a performance-focused protocol alongside testosterone cypionate or other injectables, the twice-daily schedule ensures the DHT-type androgenic tone is present during both training and recovery windows.
How Long Do Mesterolone Metabolites Remain Detectable in the Body?
This is a separate question from half-life, and it matters for competitive athletes subject to anti-doping testing. The primary glucuronide-conjugated metabolite, 1-alpha-methyl-androsterone, is the standard marker used by World Anti-Doping Agency (WADA) accredited laboratories. Traditional screening by gas chromatography with mass spectrometry detects this metabolite for approximately 5 to 7 days after a single oral dose.
However, Polet, Van Gansbeke, Geldof, Deventer and Van Eenoo (2017) at Ghent University’s Doping Control Laboratory identified a novel long-term metabolite, 1-alpha-methyl-5-alpha-androstan-3,6,16-triol-17-one, in the sulfate fraction of human urine. Using advanced selected reaction monitoring GC-CI-MS/MS techniques, this metabolite was detectable for up to 15 days after a single oral administration of Proviron (Drug Testing and Analysis, 9(11-12), 1673-1684).
Additional work by Kiousi and colleagues (2015) at the Athens doping control laboratory identified six sulfate-conjugated metabolites of mesterolone, encoded M1 through M7, with retrospectivity comparable to the main glucuronide-fraction metabolite. Two of these sulfate metabolites, designated S1 (1-alpha-methyl-5-alpha-androst-3-one-17-beta-sulfate) and S2 (1-alpha-methyl-5-alpha-androst-17-one-3-beta-sulfate), were detectable for up to 9 days after a single dose (Journal of Mass Spectrometry, 50(12), 1409-1419).
For practical purposes, athletes in tested competition should assume a detection window of at least two weeks from last administration when advanced analytical techniques are employed, and potentially longer with repeat dosing due to metabolite accumulation.
Does the Proviron Half-Life Change With Repeated Dosing?
The terminal half-life of a compound does not typically change with repeated administration. What changes is the steady-state trough concentration. With a 12-to-13-hour half-life and twice-daily dosing, mesterolone reaches steady state within approximately 2.5 to 3 days (roughly five half-lives). At steady state, the trough level before the next dose will be higher than after a single dose, because each new dose is administered before the previous one has fully cleared.
The metabolite picture is more complex. Since 1-alpha-methyl-androsterone is produced continuously with each dose and has its own elimination kinetics, metabolite accumulation occurs in parallel. The practical consequence is that men who have been taking Proviron daily for several weeks have a higher baseline androgenic activity from metabolites than men who have taken a single dose, even if the parent mesterolone levels between doses drop similarly. This partially explains why clinical effects of mesterolone often take one to two weeks to fully manifest, even though the drug itself reaches peak serum levels within 2 hours of the first dose.
How Does the Proviron Half-Life Interact With the Half-Lives of Injectable Testosterone Esters?
This is relevant because most men using Proviron are using it alongside an injectable testosterone. Testosterone cypionate has a half-life of approximately 8 days. Testosterone enanthate is similar at roughly 4.5 days. Testosterone propionate is much shorter at roughly 0.8 days. Sustanon 250, being a blend of four esters, produces a complex multi-phase release profile.
Because Proviron operates on a 12-to-13-hour cycle while injectable testosterones operate on multi-day cycles, the two compounds exist on fundamentally different pharmacokinetic timescales. Proviron’s SHBG displacement effect and DHT-type androgenic contribution are daily events, layered on top of the slow-release testosterone base. This means Proviron dosing does not need to be synchronised with injection timing. It operates independently, providing a consistent daily augmentation regardless of where you are in your injection cycle.
The one practical consideration is that some men experience a slight peak-and-trough cycle with their injectable testosterone, feeling best in the 24 to 48 hours after injection and less optimal in the days before the next injection. Adding consistent twice-daily Proviron can smooth this subjective experience by maintaining steady DHT-type androgenic tone during the trough phase of the injectable.
How Do You Verify That Your Proviron Contains the Right Amount of Mesterolone?
Pharmacokinetic data is only meaningful if your product actually contains what the label claims. Underdosed mesterolone will produce a lower Cmax, a shorter effective duration, and less SHBG displacement than correctly dosed product. Hemi Pharma UK eliminates this variable through independent batch testing by Janoshik Analytical (Prague). Each batch result is published on the lab results page, and every blister carries a QR code linking to the independently verifiable certificate of analysis at janoshik.com.
Frequently Asked Questions
What is the exact Proviron half-life?
The terminal elimination half-life of mesterolone (parent compound) is 12 to 13 hours, according to the Bayer prescribing information. Peak plasma concentration occurs approximately 2 hours after oral administration. However, the primary active metabolite, 1-alpha-methyl-androsterone, persists beyond this window, extending the total duration of androgenic activity.
Should I take Proviron once or twice daily based on its half-life?
For consistent SHBG suppression and steady androgenic support, twice-daily dosing (for example, 25mg morning and 25mg evening) is standard clinical practice. The 12-to-13-hour Proviron half-life means that twice-daily dosing maintains meaningful serum levels around the clock. Once-daily dosing is acceptable at lower total doses (25mg per day) when moderate SHBG reduction is sufficient.
How long is Proviron detectable in a drug test?
The primary glucuronide metabolite is detectable by standard screening for approximately 5 to 7 days. Advanced analytical methods targeting sulfate-fraction metabolites extend the detection window to approximately 15 days after a single dose, based on the Polet et al. (2017) findings at Ghent University. Repeated dosing may extend detection further due to metabolite accumulation.
Does the Proviron half-life make it safe for the liver?
Liver safety is determined by structural chemistry, not half-life. Mesterolone uses 1-alpha-methylation rather than the 17-alpha-alkylation found in hepatotoxic oral steroids like oxymetholone or stanozolol. This structural difference is why mesterolone does not cause cholestatic liver injury, regardless of how long you use it.
Does the Proviron half-life change if I take it with food?
The Bayer SmPC does not specify a significant food effect on mesterolone absorption. Standard clinical guidance recommends taking the tablets with liquid. Fat-soluble compounds generally show improved absorption with food, though specific food-interaction studies for mesterolone have not been published. Taking it consistently with or without food is more important than the specific choice.